Biodesix Valuation Multiples

Biodesix Overview

About Biodesix

Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.

Founded

2005

HQ

Employees

273

Website

biodesix.com

Sectors

Medical Imaging & DiagnosticsLaboratory ServicesBioTechHealthTech

Financials (LTM)

Revenue: $95M

EBITDA: ($15M)

EV

$187M

Valuation Multiples

Multiples.vc

Start free trial

Biodesix Financials

Biodesix reported last 12-month revenue of $95M and negative EBITDA of ($15M).

In the same LTM period, Biodesix generated $76M in gross profit, ($15M) in EBITDA losses, and had net loss of ($33M).

Biodesix P&L

In the most recent fiscal year, Biodesix reported revenue of $88M and EBITDA of ($18M).

Biodesix expects next 12-month revenue of XXX and NTM EBITDA of XXX

Biodesix Stock Performance

Biodesix has current market cap of $133M, and enterprise value of $187M.

Biodesix's stock price is $13.20.

Biodesix Valuation Multiples

Biodesix trades at 2.0x EV/Revenue multiple, and (12.8x) EV/EBITDA.

Biodesix Financial Valuation Multiples

As of April 20, 2026, Biodesix has market cap of $133M and EV of $187M.

Equity research analysts estimate Biodesix's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Biodesix has a P/E ratio of (4.0x).

Biodesix Margins & Growth Rates

Biodesix's revenue in the last 12 month grew by 22%.

Biodesix's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.4M for the same period.

Biodesix's rule of 40 is 16% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Biodesix's rule of X is 50% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Biodesix Public Comps

See public comps and valuation multiples for other Medical Imaging & Diagnostics and Laboratory Services comps.

Biodesix M&A Activity

Biodesix acquired XXX companies to date.

Last acquisition by Biodesix was on XXXXXXXX, XXXXX. Biodesix acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Biodesix Investment Activity

Biodesix invested in XXX companies to date.

Biodesix made its latest investment on XXXXXXXX, XXXXX. Biodesix invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).